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Abstract
Background: CD8+ T cells play an important role in control of viral replication during acute and early human
immunodeficiency virus type 1 (HIV-1) infection, contributing to containment of the acute viral burst and
establishment of the prognostically-important persisting viral load. Understanding mechanisms that impair CD8+ T
cell-mediated control of HIV replication in primary infection is thus of importance. This study addressed the relative
extent to which HIV-specific T cell responses are impacted by viral mutational escape versus reduction in response
avidity during the first year of infection.
Results: 18 patients presenting with symptomatic primary HIV-1 infection, most of whom subsequently established
moderate-high persisting viral loads, were studied. HIV-specific T cell responses were mapped in each individual
and responses to a subset of optimally-defined CD8+ T cell epitopes were followed from acute infection onwards
to determine whether they were escaped or declined in avidity over time. During the first year of infection,
sequence variation occurred in/around 26/33 epitopes studied (79%). In 82% of cases of intra-epitopic sequence
variation, the mutation was confirmed to confer escape, although T cell responses were subsequently expanded to
variant sequences in some cases. In contrast, < 10% of responses to index sequence epitopes declined in
functional avidity over the same time-frame, and a similar proportion of responses actually exhibited an increase in
functional avidity during this period.
Conclusions: Escape appears to constitute a much more important means of viral evasion of CD8+ T cell
responses in acute and early HIV infection than decline in functional avidity of epitope-specific T cells. These
findings support the design of vaccines to elicit T cell responses that are difficult for the virus to escape.
Background
Virus-specific CD8+ T cell responses are expanded as
the acute burst of viral replication occurs in primary
HIV infection [1-3] and are thought to make an impor-
tant contribution to resolution of acute viraemia and
establishment and maintenance of the level of ongoing
virus replication [4-6]. Understanding of mechanisms
that may undermine the ability of HIV-specific CD8+ T
cell responses to achieve and sustain good control of
virus replication in the critical initial phase of infection
is of importance to inform the rational design of pro-
phylactic and therapeutic strategies targeting cell-
mediated responses to induce optimal containment of
HIV infection. Mechanisms proposed to contribute to
impairment of T cell-mediated control of viral replica-
tion during acute/early infection include virus muta-
tional escape from CD8+ T cell responses [4,7],
reduction in the functional avidity of CD8+ T cell
responses (possibly due to the exhaustion and deletion
of higher avidity T cell clones [8,9]) and acquisition of
defects in the functional capacity of HIV-specific T cells
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these mechanisms to impairment of HIV control during
acute/early infection is not well understood.
HIV evolution to acquire mutations conferring partial
or complete escape from epitope-specific CD8+ T cell
responses occurs commonly at the population level
[15,16] and has been shown to take place during both
acute/early infection [3,4,6,7,17] and chronic infection
[18,19]. Evolution of mutations in or around T cell epi-
topes can promote escape via mechanisms including
impaired antigen processing of the epitope, altered bind-
ing of the epitope to the cognate human leukocyte anti-
gen (HLA) class I molecule and altered interaction of
the HLA class I-peptide complex with the T cell recep-
tor (TCR). The impact of escape from any given epi-
tope-specific T cell response will depend on the relative
contribution of that response to overall containment of
virus replication and the fitness cost associated with
viral sequence variation. In some cases, escape from the
Tc e l lr e s p o n s et oas i n g l ee p i t o p ec a nl e a dt ol o s so f
control of virus replication and disease progression
[18,19].
T h ef u n c t i o n a la v i d i t yo fTc e l lr e s p o n s e sh a sb e e n
shown to influence their efficacy in both viral and
tumour models [20-22]. Higher avidity T cell responses
tend to be more efficacious for controlling virus replica-
tion because they are sensitive to lower antigen concen-
trations and preferentially activated early in infection
when antigen is limiting, and they initiate target cell
lysis better than lower avidity T cells at any given anti-
gen density [23]. In vitro studies also suggest that HIV-
specific CD8+ T cells must exceed an epitope-depen-
dent avidity threshold in order to mediate lysis of
infected cells, suggesting that small differences in avidity
can have a very marked effect on antiviral efficacy [24].
A recent study also reported a relationship between T
cell avidity and polyfunctionality, finding that high avid-
ity HIV-specific T cells are typically polyfunctional and
capable of mediating potent suppression of viral replica-
tion in vitro [25]. However, higher avidity clones are
also more prone to becoming exhausted and deleted
from the repertoire [8,9], and their loss may be asso-
ciated with reduced control of virus replication. Mainte-
nance of high avidity clones may correlate with more
favourable disease prognosis [9].
In this study, we addressed the relative frequency with
which mutational escape and reduction in T cell response
avidity occurred in acute and early HIV infection, to gain
insight into the potential impact of these two mechan-
isms on T cell-mediated containment of virus replication
at this time. Sequence variation and escape were found to
occur much more frequently than reduction in T cell
avidity during the first year of infection.
Results
Identification of CD8+ T cell responses in subjects acutely
infected with HIV
18 patients presenting with symptomatic primary HIV-1
infection who were sampled at sequential time-points
from acute infection onwards were studied (Table 1).
The first sampling time-point was at a mean of 20 days
following onset of symptoms (DFOSx) (median = 18.5
DFOSx, range = 5-55 DFOSx), when the mean viral
load was 577,594 copies/ml plasma (range 1,200 -
4,337,100 copies/ml) and the majority of subjects had
only recently begun to seroconvert. After the acute
phase of infection, the majority of subjects controlled
virus replication relatively poorly, with only 3 patients
containing virus replication to below 2,000 HIV RNA
copies/ml (Table 1).
In each individual, we mapped the specificity of the
primary HIV-specific T cell response using an interferon
(IFN)g enzyme-linked immunosorbent spot (ELISPOT)
matrix-based peptide screening approach. Patient per-
ipheral blood mononuclear cells (PBMC) pooled from
time-points within the first six months of infection
(typically from 4-6 months FOSx) were tested for reac-
tivity to overlapping peptides spanning either the clade
B consensus (2001) sequence or (in four subjects) the
patient’s autologous virus sequence determined at the
earliest available sampling time-point. The HIV-specific
T cell response at the time of mapping targeted a mean
of 8.2 epitopic regions (range = 2-17 epitopic regions)
and the three most frequently recognised proteins were
Gag, Nef and Pol, accounting for 24%, 22% and 22% of
all epitopic regions detected, respectively.
T responses to different viral epitopes expand asyn-
chronously in primary HIV infection [3]: typically, rapid
expansion of responses to just a limited number of epi-
topes is initially observed, followed by successive waves
of expansion and contraction of responses to other epi-
topes so that the overall response breadth increases over
time, with multiple shifts occurring in the pattern of
epitope immunodominance. Having mapped the epi-
topes recognised at ~4-6 months FOSx in each patient,
we then performed a kinetic analysis of the magnitude
of the response to each epitopic region during acute/
early infection so that a subset of responses appropriate
for further study could be selected. Responses chosen
w e r et h o s et h a tw e r ep r e s e n ta tam a g n i t u d eh i g h
enough to permit characterisation at the earliest sam-
pling time-point during acute infection and remained of
sufficient magnitude for study over the first year of
infection, and where the optimal CD8+ T cell epitope
sequence within the epitopic region could readily be
identified. In total, we analysed 33 T cell responses to
HIV-1 epitopes of 24 different specificities (1-3
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Page 2 of 13epitopes/patient), located in diverse HIV-1 proteins and
restricted by a range of HLA class I alleles (Table 2).
The responses studied included some that were immu-
nodominant and others that were sub-dominant in the
individual’s acute/early HIV-specific T cell response. 16
of 33 epitopes (48%) studied were contained within Nef.
Intra-epitopic sequence variation is common during the
first year following presentation with HIV-1 infection
To address the extent to which T cell responses may have
been escaped by viral mutation, autologous virus popula-
tion sequencing of epitope-containing regions was
performed at selected time-points over at least the first
year following presentation (with the exception of patients
MM45 and MM48 whose last available sequence informa-
tion was at 213 and 204 DFOSx respectively) (Table 2).
One or more sites of amino acid variation were observed
during year 1 in or around 26/33 (79%) of the epitopes
studied. Of these, 17/33 (52%) showed only intra-epitopic
sequence variation (Table 2), 2/33 (6%) showed changes
both within the epitope (Table 2) and in the flanking
regions and 7/33 (21%) exhibited variation in the epitope
flanking regions only. In 14/19 (74%) of the cases of intra-
epitopic sequence variation, the changes became fixed in
Table 1 Clinical and sampling profiles of patients studied.
Patient HLA class I type Time of last HIV
Ab negative test
(DFOSx
1)
Time of first fully
positive HIV Ab
test (DFOSx)
First
sampling
time-point
studied
(DFOSx)
Viral load at first
PBMC sampling
time point
(RNA copies/ml
plasma)
Setpoint persisting viral load
established after the acute phase of
infection (RNA copies/ml plasma)
MM7 A*02
A*03
B*07
B*44
Cw*05
Cw*07
Evolving at 11 16 23 690,000 128,925
MM9 A*01
A*66
B*41
B*08
Cw*07
Cw*07
7 19 19 142,700 19,379
MM12 A*03
A*68
B*07
B*44
Cw*07
Cw*07
ND
2 7 16 1,555,700 97,970
MM13 A*01
A*01
B*08
B*57
Cw*06
Cw*07
ND 15 16 131,800 15,348
MM26 A*02
A*68
B*51
B*35
Cw)15
Cw*04
Evolving at 37 49 55 56,200 34,493
MM27 A*02
A*03
B*07
B*44
Cw*05
Cw*07
Evolving at 12 26 28 353,200 48,360
MM28 A*11
A*30
B*13
B*35
Cw*04
Cw*06
6 9 6 4,337,100 12,322
MM33 A*02
A*68
B*07
B*44
Cw*05
Cw*07
Evolving at 9 12 12 1,451,400 73,958
MM34 A*01
A*24
B*51
B*35
Cw*12
Cw*12
Evolving at 10 17 17 29,900 8,522
MM39 A*02
A*03
B*15
B*35
Cw*03
Cw*04
Evolving at 3 23 5 350,600 8,546
MM43 A*02
A*02
B*55
B*40
Cw*10
Cw*09
Evolving at 6 13 21 Not available
(898,100 at 27
DFOSx)
64,565
MM45 A*03
A*03
B*07
B*51
Cw*07
Cw*15
Evolving at 1 22 22 23,200 1,917
MM46 A*02
A*11
B*08
B*52
Cw*07
Cw*12
1 5 5 224,100 81,011
MM47 A*24
A*24
B*39
B*65
Cw*02
Cw*07
Evolving at -1 8 28 17,000 15,839
MM48 A*24
A*26
B*62
B*27
Cw*01
Cw*09
1 Evolving at 16 22 40,100 4,266
MM51 A*02
A*30
B*13
B*44
Cw*05
Cw*06
Evolving at 5 39 18 39,400 26,557
MM55 A*01
A*33
B*14
B*15
Cw*07
Cw*08
6 24 31 1,200 50
MM56 A*02
A*24
B*35
B*57
Cw*04
Cw*06
4 ND 14 15,000 1,023
1DFOSx = days following onset of symptoms;
2ND = not determined
Turnbull et al. Retrovirology 2011, 8:41
http://www.retrovirology.com/content/8/1/41
Page 3 of 13Table 2 Longitudinal autologous epitope sequence data.
Patient Clade B consensus epitope
sequence(s)
Autologous epitope sequence(s)
1
MM7 HLA-A3 RLRPGGKKK (Gag p17 20-28)
d23
RLRPGGKKK
d87
RLRPGGKKK
d553
RLRPGGKKK
d766
RLRPGGKKR
d934
RLRPGGKKR
HLA-A3 QVPLRPMTYK (Nef 73-82) QVPLRPMTYK QVPLRPMT/
NYK
2
QVPLRPMT/NYK QVPL/VRPMT/
NYK
QVPL/
VGPMTYK
MM9 HLA-B8 FLKEKGGL (Nef 90-97)
d26
FLKEKGGL
d54
FLKEKGGL
d105
FLKEKGGL
d273
FLKEKGGL
d343
FLKEKGGL
HLA-Cw07 KRQDILDLWVY (Nef 105-115) KRQDILDLWVY KRQD/
EILDLWVY
KRQD/
EILDLWVY
RRQEILDLWVY RRQEILDLWVY
MM12 HLA-A3 QVPLRPMTYK (Nef 73-82)
d16
QVPLRPMTYK
d40
QVPLRPMTYK
d139
QVPLRPMTYK
d230
QVPLRPMTYK
d321
QVPLRPMTYK
d487
QVPLRPMTYK
HLA-A3 QIYAGIKVK (RT 269-277) QIYAGIKVK QIYAGIKVK QIYAGIKVR QIYAGIKVR QIYAGIKVR QIYAGIKVR
MM13 HLA-B8 FLKEKGGL (Nef 90-97)
d16
FLKEKGGL
d45
FLKEKGGL
d96
FLKEK/EGGL
d275
FLKEEGGL
d544
FLKEEGGL
HLA-B57 KAFSPEVIPMF (Gag p24 30-40) KAFSPEVIPMF KAFSPEVIPMF KAFSPEVIPMF KAFSPEVIPMF KAFSPEVIPMF
HLA-B57 HTQGYFPDWQ (Nef 116-125) HTQGYFPDWQ HTQGYFPDWQ HTQGYFPDWQ HTQGYFPDWQ HTQGYFPDWQ
MM26 HLA-B7 KPQVPLRPMTY (Nef 71-81)
d55
KPQVPLRPMTY
d169
RPQVPLRPMTY
d253
RPQVPLRPMTY
d415
RPQVPLRPMTY
HLA-A2 YTAFTIPSI (RT 127-135) YTAFTIPSI YTAFTIPSI/T YTAFTIPST YTAFTIPST
MM27 HLA-A2 YTAFTIPSI (RT 127-135)
d28
YTAFTIPSV
d53
YTAFTIPSV
d81
YTAFTIPSV
d299
YTAFTIPSV/I
d466
YTAFTIPSI
MM28 HLA-A11 AAVDLSHFLK (Nef 83-92)
d9
AAVDLSHFLK
d34
AALDLSHFLK
d198
AALDLSHFLK
d405
GALDLSHFLK
MM33 HLA-B44 EEMNLPGRW (Protease 34-42)
d12
EEMNLPGRW
d96
EDMNLPGRW
d201
EDMNLPGRW
d391
EDMNLPGRW
MM34 HLA-B35 DPNPQEVVL (Gp160 78-86)
d17
DPNPQEVVL
d45
DPNPQEVVL
d192
DPN/SPQEVVL
d353
DPN/SPQEVVL
HLA-A24 RYPLTFGWCF (Nef 134-143) RYPLTFGWCF RYPLTFGWCF RFPLTFGWCF RFPLTFGWCF
MM39 HLA-A3 RLRPGGKKK (Gag p17 20-28)
d11
RLRPGGKKK
d92
RLRPGGKKK
d179
RLRPGGKKK
d358
RLRPGGKKK
HLA-A3 QVPLRPMTYK (Nef 73-82) QVPLRPMTYK QVPLRPMTYK QVPLRPMTYK QVPLRPMTYK
MM43 HLA-B40 KEKGGLEGL (Nef 92-100)
d21
KEKGGLEGL
d101
KEKGGLEGL
d228
KEKGGLEGL
d368
KEKGGLEGL
HLA-A2 ALQDSGLEV (RT 485-493) ALQDSGLEV ALQDSGLEV ALQDSGLEV ALQDSGLEV
HLA-A2 LEWRFDITL (Nef 181-189) LEWRFDITL LEWRFDITL LE/Q/P/
AWRFDITL
LAWRFDITL
MM45 HLA-A3 RLRPGGKKK (Gag p17 20-28)
d22
RLRPGGKKK
d87
RLRPGGKKK
d213
RLRPGGKKK
MM46 HLA-A2 LVWKFDSRL (Nef 181-189)
d5
LVWKFDSRL
d56
LVWKFDSRL
d175
LVWKFDSRL
d530
LVWKFDSRL
HLA-A11 RLAFHHVAR (Nef 188-196) RLAFHHVAR RLAFHHVAR RLAFHHAAR RLAFHHAAR
MM47 HLA-B14 ERYLKDQQL (Gp160 584-592)
d28
ERYLKDQQL
d57
ERYLKDQQL
d84
ERYLQDQQL
d113
ERYLKDQQL
d217
ERYLQDQQL
d402
ERYLQDQQL
HLA-A24 RYPLTFGWCY (Nef 134-143) RYPLTFGWCY RFPLTFGWCY RFPLTFGWCY RFPLTFGWCY RFPLTFGWCY RFPLTFGWCY
MM48 HLA-B27 KRWIIMGLNK
(Gag p24 131-140)
d22
KRWIIMGLNK
d50
KRWIIMGLNK
d113
KRWIIMGLNK
d204
KRWIIM/LGLNK
HLA-A24 RYPLTFGWCF (Nef 134-143) RYPLTFGWCF RYPLTFGWCF RYPLTFGWCF RYPLTFGWCF
MM51 HLA-B13 RQANFLGKI
(Gag p2p7p1p6 66-74)
d18
RQANFLGKI
d86
RQANFLGKI
d207
RQANFLGKI
d389
RQANFLGKI
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ited to a single residue; however, in two cases fixation of
substitutions at two sites occurred. Some mutations arose
very rapidly: in patients MM28 and MM47, mutations
w e r ef i x e di nt h ev i r a lp o p u l a t i o nb y3 4a n d5 7D F O S x
respectively. 6/19 (32%) had varied within 3 months FOSx,
and more than three-quarters (15/19, 79%) had varied by
6 months FOSx. For the 9 epitopes exhibiting amino acid
variation within the flanking regions, changes were typi-
cally observed at 1 or 2 sites; and the majority became
fixed within 1 year. Mutations were observed in or around
at least one of the subset of epitopes sequenced in 17 of
the 18 patients included in the study.
For 17/19 of the epitope sequences that underwent
intra-epitopic sequence variation during year 1, we had
sufficient PBMC to perform IFNg ELISPOT assays to
compare T cell recognition of titrated doses of the index
sequence and mutant epitope peptide(s). 14/17 (82%) of
the mutant epitope peptides were recognised consider-
ably less well by the primary CD8+ T cell response in
t h ep a t i e n tw h e r et h e yw e r es e l e c t e dt h a nt h ec o r r e -
sponding index sequence peptide, i.e. the half-maximal
stimulatory concentration of the mutant peptide was at
least 10-fold higher than that of the index peptide (Fig-
ure 1, a-n). These were deemed to represent T cell
escape variants. In 3/19 cases the mutant peptide(s)
were recognised with comparable efficiency to the index
sequence peptide and thus failed to meet our criteria for
an escape variant (Figure 1, o-q), although the changes
may potentially have conferred escape via effects on epi-
tope processing, which we did not address.
These data demonstrate (i) that sequence variation
within/adjacent to T cell epitope sequences occurs very
commonly during acute/early HIV-1 infection and (ii)
that in a minimum of 82% of cases, the mutations evol-
ving within the epitope resulted in impaired recognition
by the primary CD8+ T cell response.
Emergence of T cell responses to escape variant epitopes
Evidence in the literature shows that new responses to
variant epitopes can be mounted during HIV infection
[26,27]. As these responses may help to confer
continued control of viral replication, we were interested
to address whether responses emerged to the variant
peptides we defined as escape mutants. For 9/14 of the
epitopes where mutations confirmed to confer escape
were selected in acute/early infection, we measured T
cell recognition of both the index sequence and variant
epitope peptides at time-points over the first year of
infection by IFNg ELISPOT assay. A response was con-
sidered to have been expanded to the variant peptide(s)
if the magnitude of the response to the variant peptide
increased over time relative to the response to the index
peptide, or if recognition of a previously non-recognised
peptide started to be detected. In 7/9 cases, the acute-
phase T cell response was capable of at least some
recognition of the variant epitope peptide and for 5/7 of
these (Figure 2, a-e), the response to the variant
increased in magnitude over time relative to the
response to the index sequence peptide, consistent with
expansion of a response to the variant epitope. In 2/7
cases (Figure 2, f and 2g), although the variant peptide
was partially cross-recognised at the earliest time-point,
the response to the variant peptide remained relatively
stable or reduced relative to the response to the index
sequence over time. In 2/9 cases (Figure 2, h and 2i), it
appeared that a de novo response emerged following
evolution of the variant sequence because the acute-
phase T cell response showed no recognition of the var-
i a n tp e p t i d eb u tar e s p o n s ew as detected at subsequent
time-points. These results suggest that for a subset of
HIV-specific CD8+ T cell responses escaped by the
virus, the emergence of variant-specific T cell responses
o v e rt i m em a ya l l o wf o rad e g r e eo fc o n t i n u e dc o n t r o l
of viral replication.
The majority of HIV epitope-specific T cell responses
maintain stable avidity over the first year of infection
To address whether the avidity of CD8+ T cell
responses to the founder virus population was altered
over time, we measured the avidity of responses to
index sequence epitope peptides at selected time-points
over the first year FOSx by peptide-titrated IFNg ELI-
SPOT assay. All epitope-specific T cell responses
Table 2 Longitudinal autologous epitope sequence data. (Continued)
MM55 HLA-B14 DRFYKTLRAEQ
(Gag p24 166-176)
d31
DRFYKTLRAEQ
d94
DRFYKTLRAEQ
d227
DRFYKTLRAEQ
d347
DRFYKTLRAEQ
HLA-B14 ERYLKDQQL (Gp160 584-592) ERYLKDQQL ERYLKDQQL ERYLKDQQL ERYLKDQQL
Unknown RDISGWILSTY (Rev 53-63) RDISGWILSTY RDISGWILSTY RDISGWILSTY RDISGWILST/AY
MM56 HLA-B57 TSTLQEQIGW
(Gag p24 108-117)
d14
TSTLQEQIGW
d75
TSTLQEQIGW
d186
TSNLQEQIGW
d375
TSNLQEQIGW
1 The autologous virus sequence of the epitope at the indicated timepoint (day (d) FOSx is shown. Areas of amino acid variation within the epitope are indicated
in bold italics and underlined.
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Figure 1 Comparison of T cell recognition of index sequence and variant sequence peptides in IFNg ELISPOT assays.I ne a c hp a t i e n t ,
PBMC from the specified days following symptom onset were stimulated with log-fold titrations (between 10
-4 and 10
-10M) of index sequence
peptide (closed diamonds) and the variant peptide(s) that evolved during the first year post-presentation (open squares and circles). The
magnitude of the T cell response (IFNg spot-forming cells per million PBMC) was measured at each peptide concentration.
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Figure 2 T cell responses to variant epitope peptides emerge during the first year following presentation with HIV infection.F o r9
epitopes in 8 patients, PBMC from selected time-points during the first year following presentation with HIV infection were titrated against index
sequence and variant sequence peptide(s) in an IFNg ELISPOT assay. The concentration of index sequence peptide stimulating the maximal IFNg
response in the assay was determined. At each longitudinal time-point, the response to this concentration of the variant peptide(s) (black
diamonds or grey squares) is shown, expressed as a percentage of the response to the index sequence peptide at the same peptide
concentration.
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Page 7 of 13studied had avidity values within the μM to nM range at
the earliest time-point tested. When the relative avidity
of each response at the earliest time-point available (t =
0) was compared to that ~1 year after symptomatic pre-
sentation, 7 of 33 responses exhibited a ≥ 10-fold
change in avidity over this time. However, of these 7
responses, 4 underwent an increase in avidity; so
remarkably only 3/33 (9% of all the responses studied)
declined in avidity during this time-frame (Figure 3). As
described above, 19/33 (58%) of the responses analysed
were directed towards epitopes that underwent intra-
epitopic sequence variation within the first year FOSx.
When we focused on T cell responses to epitopes that
did not undergo intra-epitopic sequence variation within
the first year, we found that only 1/14 (7%) showed a ≥
10-fold decrease in avidity between t = 0 and t = 1 year
(and this was a response directed against an epitope
where there were changes in the flanking sequence, i.e.
none of the 7 responses directed against epitopes in
completely invariant sequences declined in avidity over
the first year of infection). Reduction in the avidity of
HIV-specific T cell responses thus occurs much less fre-
quently than T cell-driven escape during the first year
of HIV infection.
Discussion
It remains unclear why the strong HIV-specific CD8+ T
cell responses induced in primary infection are not
more effective in controlling virus replication. Muta-
tional escape and reduction in the functional avidity of
virus-specific T cell responses represent two mechan-
isms by which the ability of HIV-specific CD8+ T cells
to control viral replication can become impaired. To
address which of these may play a more dominant role
in reducing CD8+ T cell-mediated control of virus repli-
cation in acute/early HIV infection, we measured the
relative frequency of sequence variation/escape from,
and assessed whether there were alterations in the avid-
ity of 33 epitope-specific CD8+ T cell responses during
the first year of HIV infection in a cohort of subjects
presenting with symptomatic primary HIV infection, the
majority of whom subsequently established moderate-
high persisting viral loads.
Amino acid changes were selected for in/around
almost 80% of the epitopes studied during the first year
of infection. Although these epitopes were derived from
different HIV proteins and restricted by different class I
alleles, just under half were contained in Nef. This bias
likely arose because we deliberately sought to study
responses that were mounted during primary infection,
and several studies have demonstrated a preferential tar-
geting of acute-phase T cell responses to Nef [3,28].
The extent of the Nef bias may have resulted in our
over-estimating the frequency of occurrence of
mutational escape because Nef is genetically diverse
(reflecting the ability of the virus to tolerate sequence
variation in this protein), which is likely to facilitate the
evolution of escape mutations. However the Nef bias did
not substantially affect the conclusions from our study,
as sequence variation was observed in/around 65% of
non-Nef epitopes during the first year of infection, and
87% of the intra-epitopic changes in these epitopes were
found to confer escape.
Conversely, the approach we used to map the epitopes
recognised by the primary HIV-specific T cell response
and select a subset of responses for study may have led
to under-estimation of the frequency of responses being
escaped. Responses were typically mapped at 4-6
months FOSx, then the kinetics of expansion/contrac-
tion of responses to optimally-defined epitopes was fol-
lowed from the earliest available time-point and those
which persisted at frequencies high enough for analysis
over the first year of infection were selected for study. It
is thus conceivable that our mapping may have missed
T cell responses that expanded quickly in acute infec-
tion, were rapidly escaped, then fell to sub-detectable
magnitudes [3,6]; or that we may have excluded
responses that were escaped and had declined by 1 year.
Rapidly-escaped epitope-specific responses that could
have been missed may have included some of the high-
est avidity responses, as high avidity responses are
reported to be preferentially escaped in acute infection
[17,29]: this may also have led to under-estimation of
the proportion of responses showing a reduction in
functional avidity over the first year. Arguing against
this however is our detection of a comparable frequency
of intra-epitopic sequence variation here and in a recent
study of 5 acutely-infected individuals where the HIV-
specific T cell response was comprehensively mapped
with autologous virus sequence-based peptides and
acute/early escape from the entire response was ana-
lysed [3].
Of 33 epitopes studied, over half evolved intra-epitopic
mutations within the first year following presentation
and the majority of these mutations were confirmed to
confer T cell escape. There are, however, limitations to
the use of this approach for determining the proportion
of responses undergoing escape, including the relevance
of in vitro assays using high peptide concentrations for
predicting recognition of viruses expressing the variant
sequences [30], and the inability to evaluate the effect of
mutations on antigen processing. When analysing epi-
tope-flanking sequences, we found change(s) in regions
surrounding 7 epitopes that did not exhibit intra-epito-
pic variation, which may have affected their processing.
The true proportion of T cell responses that was
escaped may thus have been higher than we demon-
strated. Despite these caveats, we detected a high level
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Figure 3 Comparison of the functional avidity of HIV-specific T cell responses at the earliest sampling time-point tested and ~1 year
following symptomatic presentation. For each of 33 HIV-specific T cell responses, patient PBMC from the earliest sampling time-point
available (t = 0), and from t = 1 year following symptomatic presentation with HIV infection were stimulated with log-fold titrations of index
sequence peptide (between 10
-4M and 10
-10M) in an IFNg ELISPOT assay. The functional avidity of the response was determined (the peptide
concentration stimulating half the maximal IFNg response in the assay). The graph in (a) shows, for each individual response, the functional
avidity at the two time-points. Responses changing in avidity by ≥ 1 log between the two time-points are indicated with bold lines. Examples of
data for four representative responses are shown in panels (b-e).
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Page 9 of 13of viral sequence variation and escape during the first
year of HIV infection. The impact of mutational escape
on control of viral replication may however be amelio-
rated to some extent by the evolution of responses to
variant peptides (which we observed in several cases)
and/or the fitness costs incurred by the virus in achiev-
ing escape, which can be high, particularly for epitopes
are located in structurally-conserved proteins such as
Gag p24 (reviewed in [31])
When measuring the frequency of alteration in the
functional avidity of epitope-specific T cell responses
during the first year of HIV infection, we found that <
10% of responses declined in avidity by ≥ 1 log over this
period. It is unclear what level of decline in response
avidity as assessed in our in vitro IFNg ELISPOT assays
would have had a significant impact on in vivo control
of viral replication, particularly given that the mechan-
isms by which CD8+ T cells mediate control of HIV
replication in vivo are not well understood, and the rela-
tionship between response avidity and effector capacity
may not be the same for all effector functions [24,25].
H o w e v e r ,e v e ni fad e c l i n ei nr e s p o n s ea v i d i t yo f≥ 0.5
log was considered sufficient to have a significant
impact on in vivo control of viraemia, still only 5/33
(15%) of responses would have been affected by avidity
decline over the first year of infection. This was surpris-
ing and contrasts with findings made in a previous
study by Lichterfeld et al. [9], who reported that a large
proportion of high avidity T cell responses that were
immunodominant in early infection had declined in
avidity by chronic infection (typically several years into
infection). The methods used to assess response avidity
here and in the study by Lichterfeld et al. differed,
which may have affected the results obtained. Perhaps
more importantly, Lichterfeld et al.s t u d i e do n l y
responses that were initially immunodominant and of
high avidity, whereas we looked at a cross-section of
immunodominant and subdominant responses of both
high and low avidities. Work in murine chronic infec-
tion models has shown that immunodominant high
avidity T cell responses are more likely to become
exhausted/deleted in the presence of ongoing antigenic
stimulation than initially subdominant responses of
lower avidity [32,33]. Further, we assessed changes in
response avidity over only the first year of infection: the
longer interval between the time-points studied by Lich-
terfeld et al.m a yh a v eg i v e nt i m ef o rah i g h e rp r o p o r -
tion of responses to drop in avidity. Reduction in the
avidity of T cell responses may be more common in
chronic infection as T cells become exhausted by con-
tinued antigenic exposure [34].
It is interesting to consider the mechanisms that may
have contributed to the changes in T cell response avid-
i t yt h a tw eo b s e r v e d .W ef o u n do n ee x a m p l eo fa
reduction in response avidity in the absence of sequence
change in/around the epitope, which may have been due
to exhaustion and/or deletion of the highest avidity T
cell clones involved in the epitope-specific response. In
two other cases, a reduction in functional avidity
occurred in association with intra-epitopic sequence var-
iation, hence may have resulted from variant peptide-
driven expansion of T cell clones with lower avidity for
the index sequence epitope. Interestingly, we also found
four examples of increases in response avidity over the
first year of infection. Two of these occurred in associa-
tion with intra-epitopic sequence variation, and in one
of these cases it appeared that an escape mutation had
been transmitted that then reverted, stimulating expan-
sion of T cells able to recognise the original epitope
with higher avidity than the initial response [35]. In the
other epitopes, the increases in response avidity may
have reflected selection of a subset of higher avidity epi-
tope-specific cells over time [36], or maturation in
response avidity in the absence of changes in T cell
receptor usage [37].
Conclusions
The results of this study show that sequence variation
and escape occur much more frequently than reduction
in the avidity of T cell responses during the first year of
HIV infection, suggesting that escape represents a more
important means of viral evasion of CD8+ T cell control
in acute/early HIV infection (although other mechan-
isms, such as a decline in the functional capacity of
virus-specific CD8+ T cells may also contribute to
impairment of T cell control of HIV replication during
early infection). The tremendous capacity of the virus to
escape from CD8+ T cell responses (shown here and in
previous studies) poses a huge problem for the design of
HIV vaccines aiming to elicit cell-mediated immune
responses, and development of strategies for limiting
escape from vaccine-induced T cell responses is para-
mount. These may include induction of broad T cell
responses to multiple viral epitopes, individual compo-
nents of which are less likely to be escaped [17], target-
ing conserved epitopes in which viral sequence variation
is limited due to structural constraints (reviewed in
[31]), and stimulation of T cell responses that can cross-
recognise epitope variants efficiently to reduce viral
options for escape from T cell control [38,39].
Methods
Patients and blood samples
Individuals acutely-infected with HIV-1 were recruited
at the Mortimer Market Centre for Sexual Health and
HIV Research (London, UK). Subjects were mostly male
Caucasians who presented with symptoms of acute ret-
roviral illness. Study approval was obtained from The
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Page 10 of 13National Health Service Camden and Islington Commu-
nity local Research Ethics Committee and blood samples
were drawn with written informed consent. Blood was
drawn into ethylene diamine tetra-acetic acid (EDTA)
(Sigma, Gillingham, UK) and PBMC were isolated over
Histopaque 1.077 (Sigma) and cryopreserved. All sub-
jects chose not to receive antiretroviral therapy through-
out the study duration with the exception of MM7 who
received anti-retroviral therapy from 62-156 DFOSx.
The setpoint persisting viral load established in each
subject was calculated as described in [40].
HLA class I typing
Genomic DNA was purified from patient PBMC using a
QIAamp DNA blood mini kit (QIAGEN Ltd, Crawley,
UK). High resolution class I typing was performed by
t h eO x f o r dT r a n s p l a n tC e n t r e( C h u r c h i l lH o s p i t a l ,
Oxford, UK) using a polymerase chain reaction (PCR)
method with sequence-specific primer mixes.
Population sequencing of plasma virus RNA
Population sequencing of plasma viral RNA was per-
formed as previously described [3]. Briefly, HIV-1 RNA
was isolated from plasma using a QIAamp viral RNA
mini kit (QIAGEN), and cDNA was synthesized from
replicate plasma virus RNA preparations using Super-
Script III reverse transcriptase (Invitrogen Life Technol-
ogies, Carlsbad, CA, USA). Replicate cDNA samples
(200-1200 RNA molecules/reaction) were subjected to
nested PCR amplification using an Elongase enzyme kit
(Invitrogen). All PCR products were sequenced directly.
This approach enables detection of variants present at
frequencies of 20% or more in the viral quasispecies
[41]. Nucleotide changes were considered to be fixed in
the viral quasispecies if they evolved to become the sole
residue detected over time.
Synthetic peptides
P e p t i d e sw e r es y n t h e s i s e db yF M o co rT B o cc h e m i s t r y
and purchased in a peptide-amino acid format either
from Sigma or Mimotopes (Clayton, Australia).
Mapping of the HIV-specific T cell response
HIV-specific T cell responses were mapped by IFNg
ELISPOT assay using a peptide matrix screening
approach as described previously [3]. Briefly, cryopre-
served patient PBMC (typically pooled cells from two
sample time points within the first 6 months FOSx)
were tested by IFNg ELISPOT assay for responses to
matrices of peptides (18-20mers overlapping by 10aa,
each present at 10
-5M) corresponding to the HIV clade
B consensus sequence (2001) or (in four patients) the
autologous early virus sequence. From the matrix
screening a ranked list of potential epitope-containing
peptides was deduced, and putative epitope-containing
peptides were retested individually at 10
-5M in a second
round assay. Peptides stimulating responses measuring ≥
3 × background counts and ≥ 50 IFN-g spot-forming
cells per million PBMC were considered positive.
Measurement of the functional avidity of CD8
+ T cell
responses
The functional avidity of CD8+ T cell responses at
sequential time-points during the first year of HIV
infection was determined by peptide-titrated IFNg ELI-
SPOT assay. Index sequence (earliest autologous
sequence determined) peptides were titrated (between
10
-4M and 10
-11M) against a constant number of PBMC
(1.5-2 × 10
5/well). The functional avidity was deter-
mined as the peptide concentration required to elicit
half of the maximal IFNg response in the assay.
Analysis of effect of intra-epitopic sequence variation on
T cell recognition (escape analysis)
Patient PBMC (1.5-2 × 10
5/well) were stimulated with
log-fold titrations of either index or variant sequence
peptide(s) in IFNg ELISPOT assays. A variant peptide
was deemed an escape variant if its half-maximal stimu-
latory concentration was at least 10-fold higher than
that of the index sequence peptide.
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